Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock

American Journal of Medicine

Volumn 110, Issue 6, 2001, Pages 486-488

  Appoloni, O ^a   Dupont, E ^a   Vandercruys, M ^a   Andriens, M ^a   Duchateau, J ^b   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; BACTERIUM ISOLATION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; ESCHERICHIA COLI; FEMALE; GENOTYPE; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STATISTICS;

AGED; APACHE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035870597     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00656-8     Document Type: Article

References (15)

1. Friedman G., Silva E., Vincent J.L. Has the mortality of septic shock changed with time? Crit Care Med. 26:1998;2078-2086.
2. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 94:1997;3195-3199.
3. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism affects transcription. Mol Immunol. 34:1997;391-399.
4. Warzocha K., Ribeiro P., Bienvenu J., et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 91:1998;3574-3581.
5. Louis E., Franchimont D., Piron A., et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 113:1998;401-406.
6. Brinkman BM, Zuijdeest D, Kaijzel EL, et al. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm. 1995;46:32-41.
7. Kroeger K.M., Steer J.H., Joyce D.A., et al. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine. 12:2000;110-119.
8. McGuire W., Hill A.V., Allsopp C.E., et al. Variation of the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 371:1994;508-510.
9. Cabrera M., Shaw M.A., Sharples C., et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med. 182:1995;1259-1264.
10. Stüber F., Udalova I.A., Book M., et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human promoter. J Inflammation. 46:1996;42-50.
11. Westendorp R.G., Langermans J.A., Huizinga T.W., et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 349:1997;170-173.
12. Mira J.P., Cariou A., Grall F., et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality a multicenter study . JAMA. 282:1999;561-568.
13. Le Gall J.R., Lemeshow S., Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 270:1993;2957-2963.
14. Moreno R., Vincent J.L., Matos R., et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis-related Problems of the ESICM. Intens Care Med. 25:1999;686-696.
15. Dhainaut J.F., Vincent J.L., Richard C., et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock . Crit Care Med. 23:1995;1461-1469.